Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS

Similar documents
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS

EPIDEMICS AND PANDEMICS: PREDICTION, PREVENTION, CONTROL?

Chapter 38 Viral Infections

Forward Looking Statements

Viruses: Select Agents and Emerging Pathogens. Patricia Bolívar MS., CLS, PHM

Identifying, Preparing for & Reducing Pandemic Risk

DRAFT WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE GETREADYNOWGE GETREADYNOWGE GETREADYNOWGE GETREADYNOWGE.

Vaccine Innovation and Adult Immunization Landscape

Potential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections.

INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) Proposers Day

When infections go viral Zika Virus

Antiviral Chemotherapy

Linking Pandemic Influenza Preparedness with Bioterrorism Vaccination Planning

Confronting infectious diseases and the role of vaccination: A global perspective KATE ANTEYI. MD, MPH, MBA

Multiple Choice Questions - Paper 1

A conversation with Michael Osterholm on July 30, 2013 about pandemics

Emerging global health threats of animal origin

History electron microscopes

Non-reproductive tissues and cells

Influenza: The Threat of a Pandemic

Chapters 21-26: Selected Viral Pathogens

PRESENTATION AT BIOTECH INVEST 2016

Overview: Chapter 19 Viruses: A Borrowed Life

1966 CDC assessment of US Health

Non-reproductive tissues and cells

-738 proteins were found only in the ME subjects proteins were only found in PTLS samples proteins were only found in the normal controls.

THE UNREGULATED AND INFORMAL TRADE IN WILDLIFE: IMPLICATIONS FOR BIODIVERSITY AND HEALTH

TAKEDA VACCINES INNOVATION FOR GLOBAL IMPACT. RAJEEV VENKAYYA, MD President, Global Vaccine Business Unit

AMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS

Economics of Vaccine Development A Vaccine Manufacturer s Perspective

University of Colorado Denver. Pandemic Preparedness and Response Plan. April 30, 2009

Human metapneumovirus (hmpv) and parainfluenza virus 3 (PIV3) vaccine (mrna-1653)

Center for Global Health. CDC Global Health Saving Lives Overseas, Protecting Americans at Home

DOWNLOAD OR READ : THE VIRUS PDF EBOOK EPUB MOBI

Suggested Exercises and Projects 395

CE Unit. Viruses and Vaccines

Session 44 PD, Pestilence: Getting to Know the Fourth Horseman. Moderator: Jean Marc Fix, FSA, MAAA. Presenters: Martin Meltzer, Ph.D.

Part I. Content: History of Viruses. General properties of viruses. Viral structure. Viral classifications. Virus-like agents.

On behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in

Pandemic Preparedness

AFFECTED STAKEHOLDERS

Update on the development of clinical diagnostic run controls at NIBSC. Neil Almond Division of Virology

Avian Influenza (Bird Flu) Fact Sheet

DEFINING PANDEMIC. Dr Wan Noraini Wan Mohamed Noor Head of Surveillance Sector Disease Control Division, MOH Malaysia 3 May 2018

Killer Viruses: The Why and The How. Amesh Adalja

Non-reproductive tissues and cells Recommending authority/ association

Antiviral Chemotherapy

Communicable Diseases

Viruses and cancer: Should we be more afraid?

Mapping the Global Virome. Making the Unknown Known. And the World Safe From a Future of Viral Threats

Viruses. Properties. Some viruses contain other ingredients (e.g., lipids, carbohydrates), but these are derived from their host cells.

Persistent Infections

2.1 VIRUSES. 2.1 Learning Goals

H1N1 Influenza. Influenza-A Basics. Influenza Basics. April 1, History of Influenza Pandemics. April 1 September 25, 2009

CIDRAP Leadership Forum Infectious Disease BRIEFING

IS THE UK WELL PREPARED FOR A REPEAT OF THE 1918 INFLUENZA PANDEMIC?

Isolation Precautions in Clinics

Lesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease

Epidemiology Treatment and control Sniffles and Sneezes Mortality Spanish flu Asian flu Hong Kong flu The Swine flu scare

Respiratory viruses Influenza

Size nm m m

Introduction. Crowded environments where the air is re-circulated can often be heavily infected with unseen germs and viruses.

4.3.9 Pandemic Disease

Cloudbreak. March Cidara Therapeutics

5.4.8 Pandemic Disease

Evolution of influenza

Non-reproductive tissues and cells

الحترمونا من خري الدعاء

Antiviral Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

Cloudbreak. January Cidara Therapeutics

Antiviral Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

PANDEMIC INFLUENZA PREPAREDNESS: STATE CHALLENGES

INFLUENZA PANDEMIC CONTINUED FOCUS ON THE NATION S PLANNING AND PREPAREDNESS EFFORTS REMAINS ESSENTIAL

JAJ International, Inc./LuSys Laboratories, Inc.

Update of the CDC/HICPAC Guideline: Infection Prevention in Healthcare Personnel

Caribbean Actuarial Association

The Economics of Zoonotic Diseases in China

Viral Diseases. T Bamdad, PhD, Tarbiat Modares University

AVIAN FLU BACKGROUND ABOUT THE CAUSE. 2. Is this a form of SARS? No. SARS is caused by a Coronavirus, not an influenza virus.

Humisol. This Medical discovery is largely unknown for very good reasons:

Potential Use of Convalescent Plasma During a Flu Pandemic

Adjunct Faculty, Division of Epidemiology UC Berkeley School of Public Health. San Francisco Department of Public Health.

½ of all new infections are among people aged although this age group represents <25% of the sexually experienced population.

The EUA Process at CDC Michael W. Shaw, PhD

5/28/2015. Pregnancy, Birth and Postnatal for mother and baby. and Flu, oh my! An Update on Public Health Issues for Massage Therapists

Viruses. Poxviridae. DNA viruses: 6 families. Herpesviridae Adenoviridae. Hepadnaviridae Papovaviridae Parvoviridae

Laboratory Evidence of Human Viral and Selected Non-viral Infections in Canada

Product Development for Public Health & Emerging Infections

SISEA Surveillance and Investigation of Epidemic Situations in South-East Asiaww

Non-reproductive tissues and cells Recommending authority/ association

Preventing disease Promoting and protecting health

JP MORGAN HEALTHCARE CONFERENCE M. MICHELLE BERREY, MD, MPH CHIEF EXECUTIVE OFFICER JANUARY 10, 2019

SAFETY BULLETIN #3-05 November 11, 2005 Key Facts About Avian Influenza

Section 1 Individual viruses. Introduction to virology. History of viruses. Viral taxonomy

Unit 4 Student Guided Notes

Where Health Care Meets Policy. with Dr. Mike Magee

A UNIQUE NETWORK OF EXPERTISE DEDICATED TO THE FIGHT AGAINST INFECTIOUS DISEASES

Lecture 2 Evolution in action: the HIV virus

Non-reproductive tissues and cells Recommending authority/ association

Global Challenges of Pandemic and Avian Influenza. 19 December 2006 Keiji Fukuda Global influenza Programme

Transcription:

Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS MAY 2017 1

Infectious viral pathogens are a significant global health threat to mankind 2

Since the approval of the first antiviral drug in 1963, these therapeutic agents have contributed to save millions of lives. However, antiviral drugs have been unable to keep pace with the emergence of new pathogen threats. 3

Of the hundreds of viruses that are infectious to humans, only 9 are addressed with an approved antiviral drug agent. Compounding this therapeutic challenge are the three to four new viruses that are discovered to be infectious to humans each year. In recent years, Ebola, SARS, MERS, and Zika were among the many viruses that naturally emerged without a corresponding drug treatment countermeasure. 4

Infectious Human Viruses A Significant Threat to Global Health In 2013, researchers at Columbia University estimated that there were a minimum of 320,000 infectious mammal viruses awaiting discovery 219 viral species had been identified to be infectious to humans as of 2012* Not inclusive of viral strains that underly each virus species Three to four new human viruses are identified each year* Viruses account for more than two-thirds of new human pathogens* Global warming, urban crowding and transcontinental travel are expected to fuel the emergence of future viral pandemics * Center for Immunity and Evolution, University of Edinburgh 5

The economic impact of viral outbreaks 6

Beyond the cost of human lives, there are real world economic consequences associated with pandemic outbreaks. In 2003, Severe Acute Respiratory Syndrome (SARS) emerged in China and spread from Hong Kong through international transport hubs to multiple countries within days. While the SARS outbreak was contained to 774 deaths across 37 countries, the economic cost was estimated to be $30 billion over a period of just four months. Source: U.S. Centers for Disease Control and Prevention (CDC) 7

Its not a matter of if, but when the next global viral pandemic will occur 8

Bill Gates was recently quoted as saying there are really only two events that could kill 10 million people. Nuclear war and a biological outbreak, whether intentional or natural occurring. A biological outbreak of this scale has happened before when the Spanish Flu of 1918 infected 500 million people, which resulted in the deaths of an estimated 50 million* individuals. *Source: U.S. Centers for Disease Control and Prevention (CDC) 9

Our therapeutic solution 10

The Aethlon Hemopurifier The Aethlon Hemopurifier is a candidate treatment countermeasure to address a broadspectrum of viruses that are not addressed with antiviral drug therapies, including natural occurring pandemic threats and agents of bioterrorism. Additionally, the device provides a strategy to augment the benefit of approved antiviral drug regimens. 11

The Aethlon Hemopurifier A Broad-Spectrum Treatment Countermeasure Initiated & Completed >16 in vitro viral pathogen validation studies Four investigational human studies (outside U.S.) ~150 human treatment experiences Hepatitis C virus (HCV), HIV and Ebola virus (EBV) FDA medical device feasibility study concluded on March 13, 2017 12

The Hemopurifier has been validated to capture many of the world's most virulent viral threats 13

Hemopurifier in vitro capture validations Chronic & Latent Viruses Human Immunodeficiency Virus (HIV) Hepatitis C Virus (HCV) Cytomegalovirus (CMV) Epstein-Barr Virus (EBV) Herpes Simplex Virus-1 (HSV-1) 14

Hemopurifier in vitro capture validations Bioterror & Pandemic Threat Viruses Ebola Lassa MERS-CoV Smallpox (based on Monkeypox & Vaccinia models) The Hemopurifier after treating an Ebola patient 15

Hemopurifier in vitro capture validations Mosquito-Borne Viruses Chikungunya Dengue West Nile Zika 16

Hemopurifier in vitro capture validations Pandemic Influenza Viruses H1N1 Swine Flu H5N1 Bird Flu Spanish Flu of 1918 (reconstructed) Actual Spanish Flu of 1918 pandemic resulted in approximately 50 million deaths worldwide. 17

List of viruses with an approved antiviral drug 18

VIRUSES WITH AN APPROVED ANTIVIRAL DRUG AGENT AS OF APRIL 2016 1. Human Immunodeficiency Virus (HIV) 2. Hepatitis B Virus (HBV) 3. Hepatitis C Virus (HCV) 4. Cytomegalovirus (HCMV) 5. Herpes Simplex Virus (HSV) 6. Human Papillomavirus (HPV) 7. Respiratory Syncytial Virus (RSV) 8. Varicella Zoster Virus (VZV) 9. Influenza Virus (non-virulent strains) 19

9635 Granite Ridge Drive, Suite 100 San Diego, California 92123 858.459.7800 Nasdaq: AEMD www.aethlonmedical.com THIS INFORMATIONAL SUMMARY WAS LAST UPDATED ON MAY 16, 2017 This summary overview has been provided for informational purposes only. It may contain predictions and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.aethlonmedical.com 20